CytomX Therapeutics
CTMX
About: CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Employees: 121
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
950% more capital invested
Capital invested by funds: $28.8M [Q1] → $303M (+$274M) [Q2]
477% more call options, than puts
Call options by funds: $2.09M | Put options by funds: $362K
142% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 12
108.82% more ownership
Funds ownership: 56.52% [Q1] → 165.35% (+108.82%) [Q2]
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
26% more funds holding
Funds holding: 66 [Q1] → 83 (+17) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Barclays
Etzer Darout
|
$3.5
|
Overweight
Assumed
|
17 Sep 2025 |
|
Oppenheimer
Matthew Biegler
|
$7
|
Outperform
Initiated
|
31 Jul 2025 |
Financial journalist opinion
